文献速递神经免疫

造血干细胞移植治疗多发性硬化的长期临床结局

Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
PubMed 文献 · Neurology · 2021-02-22

复发缓解型患者5年和10年无残疾恶化生存率分别为85.5%和71.3%,且EDSS显著降低;BEAM+ATG预处理方案与降低NEDA-3失败风险独立相关。

要点

  • aHSCT可使多数MS患者避免残疾恶化,复发缓解型患者10年无残疾恶化生存率达71.3%。
  • 复发缓解型患者移植后EDSS显著降低,年均变化-0.09。
  • BEAM+ATG预处理方案与降低NEDA-3失败风险独立相关(HR 0.27)。

核心结论

  • aHSCT可防止多数MS患者残疾恶化,并在复发缓解型患者中诱导持久的残疾改善。
  • BEAM+ATG预处理方案与更显著抑制临床复发和MRI炎症活动相关。

研究设计与样本

  • 中位基线EDSS评分为6(范围1-9),平均随访6.2年(±5.0年)。

主要发现

  • 复发缓解型患者5年和10年无残疾恶化生存率分别为85.5%(95%CI 76.9%-94.1%)和71.3%(95%CI 57.8%-84.8%)。
  • 进展型患者5年和10年无残疾恶化生存率分别为71.0%(95%CI 59.4%-82.6%)和57.2%(95%CI 41.8%-72.7%)。
  • 复发缓解型患者aHSCT后EDSS显著降低(p=0.001;年均变化-0.09,95%CI -0.15%至-0.04%)。
  • BEAM+ATG预处理方案与降低NEDA-3失败风险独立相关(HR 0.27,95%CI 0.14-0.50,p<0.001)。
  • 3例患者在aHSCT后100天内死亡(1.4%);2007年后移植的患者无死亡。

关键数值与推荐

  • 复发缓解型患者5年无残疾恶化生存率85.5%(95%CI 76.9%-94.1%),10年71.3%(95%CI 57.8%-84.8%)。
  • 进展型患者5年无残疾恶化生存率71.0%(95%CI 59.4%-82.6%),10年57.2%(95%CI 41.8%-72.7%)。
  • BEAM+ATG方案与NEDA-3失败风险降低相关,HR 0.27(95%CI 0.14-0.50),p<0.001。
  • 移植后100天内死亡3例(1.4%),2007年后无死亡。

临床怎么用

  • aHSCT可作为多发性硬化(尤其复发缓解型)患者的治疗选择,以诱导持久疾病缓解。
  • 选择BEAM+ATG预处理方案可能更有效抑制临床复发和MRI炎症活动。
  • 需关注移植后早期(100天内)死亡风险,2007年后移植患者未发生死亡。

局限性

  • 本研究为Class IV证据,非随机对照设计,可能存在选择偏倚。
  • 随访时间平均6.2年,部分患者失访或数据不完整可能影响长期结局评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether autologous hematopoietic stem cell transplantation (aHSCT) is able to induce durable disease remission in people with multiple sclerosis (MS), we analyzed the long-term outcomes after transplantation in a large cohort of patients with MS. METHODS: To be included, a minimum dataset (consisting of age, MS phenotype, Expanded Disability Status Scale [EDSS] score at baseline, information on transplantation technology, and at least 1 follow-up visit after transplantation) was required. RESULTS: Two hundred ten patients were included (relapsing-remitting [RR] MS 122 [58%]). Median baseline EDSS score was 6 (1-9); mean follow-up was 6.2 (±5.0) years. Among patients with RRMS, disability worsening-free survival (95% confidence interval [CI]) was 85.5% (76.9%-94.1%) at 5 years and 71.3% (57.8%-84.8%) at 10 years. In patients with progressive MS, disability worsening-free survival was 71.0% (59.4%-82.6%) and 57.2% (41.8%-72.7%) at 5 and 10 years, respectively. In patients with RRMS, EDSS significantly reduced after aHSCT (p = 0.001; mean EDSS change per year -0.09 [95% CI -0.15% to -0.04%]). In patients with RRMS, the use of the BCNU+Etoposide+Ara-C+Melphalan (BEAM) + anti-thymocyte globulin (ATG) conditioning protocol was independently associated with a reduced risk of no evidence of disease activity 3 failure (hazard ratio 0.27 [95% CI 0.14-0.50], p < 0.001). Three patients died within 100 days from aHSCT (1.4%); no deaths occurred in patients transplanted after 2007. CONCLUSIONS: aHSCT prevents disability worsening in the majority of patients and induces durable improvement in disability in patients with RRMS. The BEAM + ATG conditioning protocol is associated with a more pronounced suppression of clinical relapses and MRI inflammatory activity. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for people with MS, aHSCT induces durable disease remission in most patients.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Boffa G, Massacesi L, Inglese M, et al. Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. Neurology. 2021. PMID: 33472915. doi:10.1212/WNL.0000000000011461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。